In emergency department patients with asthma exacerbation, bronchodilation success occurred in 2/21 glucagon recipients versus 3/25 placebo recipients.
In plain wordsIn patients with asthma exacerbation, glucagon produced similar bronchodilation success to placebo.
- Peptide
- Glucagon
- Outcome
- No significant changeSuccessful bronchodilation at 10 minutes
- Study
n = 46
- Comparator
- Saline placebo
- Outcome group
- Respiratory function · Respiratory
- Studied dose
- 0.03 mg/kg · intravenousAs given in this study (human).
Measurements
- Successful bronchodilation
- 2 patients
- glucagon
- Successful bronchodilation
- 9.5%
- glucagon
- Successful bronchodilation
- 3 patients
- placebo
- Successful bronchodilation
- 12%
- placebo
- Difference in success
- −2.5%
- glucagon versus placebo
- 95% CI of difference in success
- −20.4 to 15.4%
- glucagon versus placebo
Source sentences
Success occurred in 2 (9.5%) of 21 glucagon-treated patients and 3 (12%) of 25 placebo-treated patients (95% confidence interval [CI] for difference of -2.5% [-20.4% to 15. 4%]).
4 context sentences(design, population, supporting numbers)
Successful bronchodilation was a PEFR increase of 60 L/min at 10 minutes.
We conducted a randomized, double-blind, placebo-controlled study at 2 university-affiliated community teaching hospital EDs (annual census 90,000).
ED patients 18 to 50 years old with asthma exacerbation and peak expiratory flow rate (PEFR) less than 350 L/min were eligible.
Patients were randomly assigned to receive glucagon 0.03 mg/kg or an equivalent volume of saline solution intravenously.